Dr. Adelson has been recognized as one of the foremost experts on pediatric head injury , lecturing around the United States and the world. Now he joined Phoenix Children's to expand a program that surpasses the typical model of pediatric care. For some, it's playing a musical instrument. For others, it's painting. But for P. David Adelson, MD, FACS, FAAP, the director of the Hospital's Barrow Neurological Institute and chief of neurosurgery, his passion is a bit atypical. "My hobby is neuroscience," he says. "The heart's a pump, the kidney's a filter – those are all simple functions which are there to support who we are and what we do." But the brain controls it all, he says. "I just looked at the brain and neurosciences as the next frontier; studying something of which I would never get bored." Dr. Adelson has been recognized as one of the foremost experts on pediatric head injury clinical management, lecturing around the United States and the world. He has been published in numerous medical and scientific journals defining "state-of-the art" in the care of children with traumatic brain injuries. The path to Phoenix Children's Hospital Dr. Adelson came to Phoenix in January from Pittsburgh, where he served as the A. Leland Albright Endowed Professor of Neurosurgery/Pediatric Neurosurgery at Children's Hospital of Pittsburgh and Vice Chairman, (Research) at the University of Pittsburgh School of Medicine , one of the most prominent neurosurgical departments in the country.
The Arizona Bioscience Industry is on the move and making great strides forward in discovering and delivering solutions to some of the world’s greatest challenges: The Arizona Bioindustry Association provides the connections, resources, and support that are moving us forward... faster. subscribe to our mailing list and get the AZBio IN THE LOOP each Monday.
The Greener Side of Bio
AZBio Board Chair and Co-Founder of Algae Biosciences, Glen Galster , moderates this panel discussion on the state of Arizona's green bio industry amd whwere it's going with Leif P. Christoffersen , Director of Biomass Integration, Yulex Corporation . Leif is responsible for advancing Yulex’s energy, efficiency and biomass initiatives. Prior to Yulex, Christoffersen played a key role in establishing the E.O. Wilson Biodiversity Foundation (EOWBF) with whom he maintains an active advisory role. He also spent over five years at the Diversa Corporation (Verenium Corporation and BP Biofuels), where he managed bioprospecting collaborations, as well as managed Diversa’s grants program, coordinated their scientific advisory board, and supported their international business development efforts. Christoffersen has also served as a climate change adviser to the Executive Director of UNEP at COP1 and COP2 of the Climate Change Convention (UNFCCC). At the start of his career, he worked with subsistence farmers in Costa Rica and Kenya to support and promote agroforestry practices, which included setting up exportation of organic produce. Christoffersen holds a degree from Hobart College (BA, Economics) and the University of California, San Diego (MBA, Rady School of Management). Ben Cloud , President and CEO, Phyco Biosciences, Inc ., brings over 30 years of experience as a farmer and farmland developer with operations in Arizona and Southern California. His significant experience in production agriculture including drip-micro irrigation systems and design, cropping systems, processing and marketing have contributed to the development of the Phyco production platform and business approach (To learn more, click here .) and Josh Hottenstein of the Cleantech Open
Leadership Insights - Panel
Heather Morel, VP/GM McKesson Specialty Health, Dr. Jeffrey Trent, CEO and Chief Scientific Officer, TGen, Michele Y. Halyard, M.D, vice dean, Mayo Medical School – Arizona Campus, Dr. Ronald Korn, Medical Director, Virginia G. Piper cancer Center.
Tying it all together for start up success
Alan Nelson is heading the Predictive Health Analytics Initiative that aims to change the paradigm in healthcare from treating late stage disease to early diagnosis and preventive therapies that are cost-effective. He served as the Executive Director of the Biodesign Institute at ASU and holds professorships in Bioengineering and physics. He is the founder and CEO of three companies, the most recent being VisionGate, the innovator of the LuCED lung cancer early detection test. VisionGate was awarded the start-up of the year award at the recent Governors’ celebration of innovation. Alan has a PhD in Biophysics from Berkeley, holds 66 issued patents, and has published over 100 scholarly papers in biomedical imaging.
From Discovery to Development to Delivery: Biodesign
Raymond N. DuBois, MD, PhD , executive director of The Biodesign Institute at Arizona State University explains the history and the value of biodesign and shares a look at the bioinspired, use inspired, research being done by innovative teams at The Biodesign Institute in their three focus areas of health, energy, and security.
Arbsource was founded to transform wastewater treatment from a costly energy liability into a valuable resource through state-of-the-art microbial electrochemical cell technologies. Our team includes domain experts in the water industry passionate about contributing to a safe, secure, and sustainable water infrastructure with our award-winning Arbcell biotechnology.
Paul Keim, Phd - 2012 Bioscience Researcher of the Year
Dr. Paul Keim is the Cowden Endowed Chair of Microbiology at Northern Arizona University (NAU), the Director of Pathogen Genomics at the Translational Genomics Research Institute (TGen) and research affiliate at Los Alamos National Laboratory (LANL). Dr. Keim’s research focuses on the advancement of forensics and genomics analysis of bacterial pathogens. You may know this globally recognized researcher as ” Doctor Anthrax” (a moniker he gained after 9-11) but there is a lot more to the work Dr. Keim and his team focus on every day.